ABUS vs CARR · P/E 5.4, rev $6.2M vs P/E 43, rev $5.15B
Arbutus Biopharma Corp (ABUS) versus Carrier Global Corp (CARR) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Carrier Global Corp (CARR) is a building products & equipment company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CARR revenue for 2024-12-31 was $5.15B. Net income was $5.71B. Revenue was down 14.0% from 2024-09-30 to 2024-12-31. CARR currently screens at market cap $53.05B and trailing P/E 42.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CARR currently screens at market cap $53.05B and trailing P/E 42.6.
Not investment advice. Open the ABUS and CARR stock pages for the full models.
Not investment advice.